Journal News

JLR: Sphingolipids and retinal degeneration

Dawn Hayward
Sept. 1, 2016

Two uses for the same drug. It’s been done before with success. Take aspirin, which alleviates pain and is a blood thinner. Or Wellbutrin, which helps smokers quit and is an antidepressant. In a recently published paper in the Journal of Lipid Research, researchers took a multiple sclerosis drug called Gilenya from Novartis and gave it a new use: treatment of retinal degeneration.

Gilenya, a multiple sclerosis drug, may have a new use as a treatment for retinal degeneration.

Why Gilenya? Gilenya, which also goes by the name FTY720, initially was used in multiple sclerosis, a central nervous system disorder involving the destruction of certain nerve cells. Gilenya is an altered version of a natural product and has immunosuppressive effects, particularly through the blockade of sphingolipid synthesis. This last point is key, as retinal degeneration also is known to involve sphingolipid biosynthesis.

Retinal degeneration is a catchall term for a group of diseases whose hallmark is photoreceptor cell death. This cell death has many contributing factors, one of which is ceramide, a sphingolipid whose role in retinal degeneration has been investigated by the group of Nawajes Mandal at the University of Oklahoma Health Sciences Center. In fact, in previously published work, the Mandal group identified ceramide as a critical player in retinal degeneration by using Gilenya in a rat model of light-induced retinal degeneration.

In the current JLR study, Mandal and colleagues turned their focus to a laboratory rat model, one which more frequently is used in the retinal degeneration field. This rat model closely matches how retinal degeneration happens in humans. Using this popular model gives a better idea of the effects of the drug. These transgenic animals start losing their sight at post-natal day 22 and have 50 percent photoreceptor death at postnatal day 45. This occurs because they have a mutated rhodopsin gene.

The investigators administered Gilenya to these rats at both the early and late stages of the disease and examined eye health, gene expression and sphingolipid levels. With early dosing of Gilenya came improved rod and cone function as well as lowered ceramide biosynthesis gene expression, two positive signs of improvement. In addition, the investigators noticed that the sphingolipid profile, a feature that was altered in the disease model, was reset, and they observed normal levels of associated enzymes were observed with Gilenya administration.

While Gilenya may appear to be a winner for retinal degeneration treatment, many questions remain. First, the exact pathway between ceramide biosynthesis and photoreceptor cell death needs to be established. Second, the precise mechanism of action of Gilenya also needs to be established. And, of course, many more studies with this drug in animal models have to be completed.

Still, this study makes a significant contribution to the search for retinal- degeneration drugs. Treatments for this disease are few and far between, and beginning with a Food and Drug Administration-approved drug is a good start to alleviating this disorder.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Dawn Hayward

Dawn Hayward earned a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.